FibroGen
$9.71
83
+$0.69+7.65% Wednesday 21:00
Statistics
Day High
9.75
Day Low
9.23
52W High
21.94
52W Low
4.85
Volume
31,124
Avg. Volume
32,974
Mkt Cap
39.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
2MarExpected
Expected EPS
-3.88585
Actual EPS
N/A
Financials
-23.41%Profit Margin
Unprofitable406.57MRevenue
-95.16MNet Income
Analyst Ratings
$43.00Average Price Target
The highest estimate is 43.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow FGEN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Akebia Therapeutics
AKBA
Mkt Cap585.97M
GSK
GSK
Mkt Cap94.51B
Astrazeneca
AZN
Mkt Cap256.58B
AMGEN
AMGN
Mkt Cap160.66B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Pfizer
PFE
Mkt Cap140.15B
Gilead Sciences
GILD
Mkt Cap148.78B
About
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Thane Wettig
Employees
225
Country
US
ISIN
US31572Q8087
Listings
0 Comments
Share your thoughts
FAQ
What is FibroGen stock price today?▼
The current price of FGEN is $9.71 USD — it has increased by +7.65% in the past 24 hours. Watch FibroGen stock price performance more closely on the chart.
What is FibroGen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange FibroGen stocks are traded under the ticker FGEN.
Is FibroGen stock price growing?▼
FGEN stock has risen by +0% compared to the previous week, the month change is a +6% rise, over the last year FibroGen has showed a +1,941.63% increase.
What is FibroGen market cap?▼
Today FibroGen has the market capitalization of 39.28M
When is the next FibroGen earnings date?▼
FibroGen is going to release the next earnings report on March 02, 2026.
What were FibroGen earnings last quarter?▼
FGEN earnings for the last quarter are 49.61 USD per share, whereas the estimation was -4.01 USD resulting in a +1,338.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is FibroGen revenue for the last year?▼
FibroGen revenue for the last year amounts to 406.57M USD.
What is FibroGen net income for the last year?▼
FGEN net income for the last year is -95.16M USD.
How many employees does FibroGen have?▼
As of February 03, 2026, the company has 225 employees.
In which sector is FibroGen located?▼
FibroGen operates in the Health Care sector.
When did FibroGen complete a stock split?▼
The last stock split for FibroGen was on June 17, 2025 with a ratio of 1:25.
Where is FibroGen headquartered?▼
FibroGen is headquartered in San Francisco, US.